New CAR T-Cell therapy extends remission in heavily relapsed multiple myeloma patients
A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site. Results of the trial, published recently in the New England Journal of Medicine, were significantly better than …